What's the difference between the 1.7mg and 2.4mg Wegovy doses?

What actually changes when you move from 1.7mg to 2.4mg?

Semaglutide works by activating GLP-1 receptors involved in appetite regulation and the feeling of fullness after eating. The effect is dose-dependent: higher doses tend to produce stronger appetite suppression. The step from 1.7mg to 2.4mg is the final increase in the standard titration, and it often brings a noticeable shift in how satisfied you feel after smaller portions.

The Wegovy titration schedule exists partly to manage tolerability. Gastrointestinal side effects (nausea, loose stools, indigestion) are most common when a dose increases, and moving from 1.7mg to 2.4mg is no different. Most people find any new symptoms settle within a fortnight, though the experience varies. For some, 1.7mg already does the job well enough that their prescriber may choose to stay there; for others, the 2.4mg step is where results become more consistent with what the trials showed.

It's worth understanding what the trial data actually reflect. In the STEP 1 trial, published in the New England Journal of Medicine, adults who reached and maintained the 2.4mg dose achieved an average body-weight reduction of around 15% over 68 weeks. The 1.7mg dose is not a therapeutic destination in the licensed schedule, it's a bridge, and if you want to understand what the 0.75mg Wegovy dose involves earlier in the sequence, that page explains its role in the titration. Whether crossing it makes sense for you depends on how you've tolerated previous increases and what your prescriber observes at review.

For full details on the Wegovy dose progression, each step has its own rationale.

Does staying on 1.7mg instead of advancing affect results?

It can. The licensed maintenance dose is 2.4mg, and the clinical evidence base for Wegovy's weight management outcomes (the figures that informed NICE's recommendation of semaglutide (TA875)) reflects outcomes at that dose. Staying at 1.7mg indefinitely is an off-label use of the titration schedule, and it isn't what clinical studies were designed around.

That said, there are legitimate clinical reasons a prescriber might keep someone at 1.7mg. Persistent side effects that haven't fully settled, a specific health history, or simply a cautious approach to any further dose increase are all factors a clinician weighs. The decision is never about impatience, it's about what the evidence and your own presentation support.

NICE guidance on semaglutide notes that if a patient achieves less than 5% weight loss after six months at the maintenance dose, continuing treatment should be reviewed. This threshold is tied to 2.4mg as the maintenance point, which gives the prescriber a clear benchmark. If you're curious how the different Wegovy strengths each sit within the licensed framework, that page sets it out in detail.

How do the two doses compare side by side?

The table below lays out the key factual differences between the two steps.

Numbers in the table are drawn from the STEP 1 trial and NICE TA875. The NHS medicines page for semaglutide also covers the titration schedule in patient-level language.

Can your prescriber decide the right dose without you moving up?

Yes. A prescriber who reviews your progress at 1.7mg has the clinical authority to hold that dose if the risk-benefit balance supports it. Good clinical oversight isn't about following a schedule mechanically; it's about reading the individual picture. That's partly why clinical re-review before every repeat prescription matters as much as it does.

If you're feeling uncertain (perhaps you've had a difficult time with side effects at earlier steps, or you're unsure whether 1.7mg is working) that's exactly the kind of conversation a prescriber should be having with you before your next pen is issued. The timing between doses also plays a role in tolerability, so it's worth raising if you've been stretching intervals.

For anyone comparing Wegovy options more broadly, the Wegovy price comparison page sets out what UK private treatment typically costs at different stages. And for a fuller look at what the treatment involves before starting, our weight management overview covers the options a prescriber might discuss with you. Which dose is right for you is a clinical decision our prescribers work through with you, not a call made at checkout.